Use of ketolides in combination with other drugs to treat experimental toxoplasmosis.
Use of ketolides in combination with other drugs to treat experimental toxoplasmosis.
复制标题
使用酮内酯与其他药物联合治疗实验性弓形虫病。
DOI：
10.1093/jac/42.5.665
复制
发表时间：
1998
期刊：
影响因子：
--
通讯作者：
Remington,JS
中科院分区：
文献类型：
--
作者：
Araujo,FG;Khan,AA;Bryskier,A;Remington,JS
由于需要联合治疗来治疗人类弓形虫病，我们在弓形虫病小鼠模型中检查了酮内酯HMR 3004和HMR 3647与阿托伐醌、克林霉素或磺胺嘧啶的组合。口服50 mg/kg/天剂量的HMR 3004可保护30%的致死性弓形虫感染小鼠。当与非保护性剂量的阿托伐醌、克林霉素或磺胺嘧啶联合给药时，相同剂量保护了100%的感染小鼠。在25 mg/kg/天HMR 3647组中观察到相似结果。这些结果表明，这些药物组合对治疗小鼠弓形虫病是高度有效的。
Because combination therapy is required to treat human toxoplasmosis, we examined combinations of the ketolides HMR 3004 and HMR 3647 with atovaquone, clindamycin or sulphadiazine in a murine model of toxoplasmosis. An oral dose of 50 mg/kg/day of HMR 3004 protected 30% of mice lethally infected with Toxoplasma gondii. The same dose protected 100% of infected mice when administered in combination with non-protective doses of atovaquone, clindamycin or sulphadiazine. Similar results were noted with 25 mg/kg/day of HMR 3647. These results demonstrate that these drug combinations are highly effective for treating toxoplasmosis in mice.